Skip to main content

Table 2 Methotrexate therapy effect on pain intensity according to the McGill pain index and avascular osteonecrosis chronic pain evaluation

From: Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis

Patient no. McGill pain index reductiona Avascular osteonecrosis pain reductionb Composite effectc
Responder
 14 Yes (11.8%) N/A Yes
 10 Yes (18.2%) N/A Yes
 11 Yes (20.0%) N/A Yes
 12 Yes (36.8%) N/A Yes
 13 Yes (31.4%) N/A Yes
 8 Yes (75.7%) Yes (≥50%) Yes
 1 Yes (24.5%) Yes (≥50%) Yes
 3 Yes (34.8%) Yes (≥50%) Yes
 4 No (−19.5%) Yes (≥50%) Yes
 9 No (−2.4%) Yes (≥50%) Yes
Nonresponder
 6 No (−25.6%) No No
 7 No (−9.6%) No No
 2 No (−29.7%) N/A No
 5 No (−2.6%) N/A No
  1. N/A not applicable
  2. aNegative values indicate increase of the index
  3. bAvascular osteonecrosis pain as defined in Fig. 1d
  4. cComposite effect means either avascular osteonecrosis pain reduction or lower McGill pain index or both